Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Taysha Gene Therapies Gross Margin 2020-2024 | TSHA

Current and historical gross margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current gross profit margin for Taysha Gene Therapies as of September 30, 2024 is %.
  
Taysha Gene Therapies Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-09-30 $0.01B $0.01B 100.00%
2024-06-30 $0.01B $0.01B 100.00%
2024-03-31 $0.01B $0.01B 100.00%
2023-12-31 $0.02B $0.02B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.381B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $25.626B 8.41
Dr Reddy's Laboratories (RDY) India $12.997B 24.87
BridgeBio Pharma (BBIO) United States $5.365B 0.00
Bausch Health Cos (BHC) Canada $2.752B 2.03
Supernus Pharmaceuticals (SUPN) United States $2.003B 27.28
Amphastar Pharmaceuticals (AMPH) United States $1.835B 11.03
Personalis (PSNL) United States $0.442B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.034B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00